March 14th 2024
Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.
Chemo/Immunotherapy Confers Greater Therapy-Related MDS/AML Risk in Survivors
August 3rd 2023Investigators note that although therapy-related myelodysplastic syndromes or acute myeloid leukemia are not common, efforts to reduce treatment-associated toxicity in survivors of lymphoid neoplasms are needed given the poor prognosis associated with the diagnosis.
Ropeginterferon Is NCCN-Recommended Preferred Therapy in Polycythemia Vera
May 29th 2023Ropeginterferon alfa-2b-njft has been moved to preferred status in the National Comprehensive Cancer Network guidelines for polycythemia vera based on data supporting the agent’s superior efficacy and safety in high- and low-risk populations.
Momelotinib May Set New Standard in Myelofibrosis, Expert Says
February 14th 2023“Transfusion independence is the key to my excitement [with] momelotinib as a drug. I will likely use it in most patients in the second-line setting,” says an expert from the University of Texas MD Anderson Cancer Center.
Reduction in Transfusion Dependency Observed With Low-Dose Lenalidomide for Myelodysplastic Syndrome
December 12th 2022Findings from the final analysis phase 3 SINTRA-REV trial indicated that lenalidomide lowered the risk of transfusion dependency when administered at a low dose in patients with myelodysplastic syndrome.